Skip to Content
Merck

Impact of linker length on the activity of PROTACs.

Molecular bioSystems (2010-10-06)
Kedra Cyrus, Marie Wehenkel, Eun-Young Choi, Hyeong-Jun Han, Hyosung Lee, Hollie Swanson, Kyung-Bo Kim
ABSTRACT

Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations, a small molecule-based novel technology termed "PROteolysis TArgeting ChimeraS (PROTACs)" has been developed, targeting proteins for degradation at the post-translational level. Despite the promising potential of PROTACs to serve as molecular probes of complex signaling pathways, their design has not been generalized for broad application. Here, we present the first generalized approach for PROTAC design by fine-tuning the distance between the two participating partner proteins, the E3 ubiquitin ligase and the target protein. As such, we took a chemical approach to create estrogen receptor (ER)-α targeting PROTACs with varying linker lengths and the loss of the ER in cultured cells was monitored via western blot and fluorometric analyses. We found a significant effect of chain length on PROTAC efficacy, and, in this case, the optimum distance between the E3 recognition motif and the ligand was a 16 atom chain length. The information gathered from this experiment may offer a generalizable PROTAC design strategy to further the expansion of the PROTAC toolbox, opening new possibilities for the broad application of the PROTAC strategy in the study of multiple signaling pathways.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
VH 032 amide-alkyl C3-acid, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-methylamino-PEG1-NH2 hydrochloride
Sigma-Aldrich
C5 Lenalidomide-PEG6-Butyl NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG5-CO2H, ≥95%
Sigma-Aldrich
Pomalidomide-piperazine-C1-4-piperidine hydrochloride
Sigma-Aldrich
4-Aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride, ≥95%
Sigma-Aldrich
Thalidomide-NH-PEG2-COOH, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-C6-PEG3-butyl chloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG5-NH2 hydrochloride
Sigma-Aldrich
C5 Lenalidomide-difluoroPEG1-C4-piperazine Hydrochloride, ≥95%
Sigma-Aldrich
2,6-Piperidinedione, 3-[(3-aminophenyl)amino] hydrochloride, ≥95%
Sigma-Aldrich
Thalidomide-4-hydroxyacetate, ≥95.0%
Sigma-Aldrich
(S,R,S)-AHPC-di-trimethylamide-dioxodisulfide-carbonate ester
Sigma-Aldrich
L-Prolinamide, N-[3-[2-(2-aminoethoxy)ethoxy]-1-oxopropyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- HCl, ≥95.0%
Sigma-Aldrich
Pomalidomide acetic acid, ≥95.0%
Sigma-Aldrich
3-[1,3-Dihydro-4-(5-hydroxy-1-pentyn-1-yl)-1-oxo-2H-isoindol-2-yl]-2,6-piperidinedione, ≥95.0%
Sigma-Aldrich
Pomalidomide-benzyl-piperazine hydrochloride
Sigma-Aldrich
Pomalidomide 4′-PEG3-amine hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-C2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-acetamido-O-PEG2-C1-acid, ≥95%
Sigma-Aldrich
VH 032 amide-PEG3-acid, ≥95.0%
Sigma-Aldrich
Carbamic acid, N-[2-(1-piperazinyl)ethyl]-, 1,1-dimethylethyl ester, ≥95%
Sigma-Aldrich
VH 032 amide-PEG2-acid, ≥95%
Sigma-Aldrich
3-((4-(Piperidin-4-yl)phenyl)amino)piperidine-2,6-dione hydrochloride, ≥95%
Sigma-Aldrich
Opto-pomalidomide, ≥95%
Sigma-Aldrich
Opto-thalidomide-O-acetamide-C4-NH2 hydrochloride
Sigma-Aldrich
Pomalidomide-PEG4-CO2H
Sigma-Aldrich
Pomalidomide-PEG6-CO2H
Sigma-Aldrich
Pomalidomide-C6-CO2H, ≥98%
Sigma-Aldrich
Pomalidomide-PEG6-NH2 hydrochloride, ≥98%